Ernexa Therapeutics (ERNAW) Cash from Investing Activities (2010 - 2026)
Ernexa Therapeutics' (ERNAW) quarterly Cash from Investing Activities came in at -$2000.0 in Q1 2026, up 86.67% on a QoQ basis from -$15000.0 in Q4 2025.
Powered by 
Analysis
Ernexa Therapeutics (ERNAW) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Ernexa Therapeutics (ERNAW) has 17 years of Cash from Investing Activities data on file, last reported at -$2000.0 in Q1 2026.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36000.0 (changed N/A YoY) and the FY2025 annual result came in at -$37000.0, up 89.86% from the prior year.
- Cash from Investing Activities grew to -$2000.0 in Q1 2026, from -$15000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $129000.0 in Q4 2022 to a low of -$249000.0 in Q2 2024.
- A 5-year average of -$44800.0 and a median of -$31000.0 in 2022 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 187.76% in 2022, down 8600.0% in 2022.
- Tracing ERNAW's Cash from Investing Activities over 5 years: stood at $129000.0 in 2022, then slumped by 114.73% to -$19000.0 in 2023, then changed by 0.0% to -$19000.0 in 2024, then grew by 21.05% to -$15000.0 in 2025, then soared by 86.67% to -$2000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$2000.0 (Q1 2026), -$15000.0 (Q4 2025), and -$19000.0 (Q3 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Ernexa Therapeutics | 67,312.70 | 67,312.70 | - | -3,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2024 | -19,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -97,000.00 |
| Dec 31, 2023 | -19,000.00 |
| Dec 31, 2022 | 129,000.00 |
| Sep 30, 2022 | -43,000.00 |
| Jun 30, 2022 | -87,000.00 |
| Mar 31, 2022 | -46,000.00 |
| Dec 31, 2021 | -147,000.00 |
| Sep 30, 2021 | -22.86 Mn |
| Jun 30, 2021 | -1,000.00 |
| Mar 31, 2021 | 267,000.00 |
| Dec 31, 2020 | -12,823.00 |
| Jun 30, 2020 | -21,720.00 |
| Mar 31, 2020 | -4,457.00 |
| Dec 31, 2019 | -101,000.00 |
| Sep 30, 2019 | -246,000.00 |